Treatment of a vancomycin-resistant Enterococcus faecium ventricular drain infection with quinupristin/dalfopristin and review of the literature.
Central nervous system infections involving vancomycin-resistant Enterococcus faecium (VREF) are infrequently described and pose significant therapeutic difficulties, because these organisms are intrinsically resistant to many antibiotics. We describe the use of intrathecal quinupristin/dalfopristin to treat a VREF-associated infection in a neuro--surgical patient.
Tan
T Y
TY
Department of Microbiology, University Hospital of Wales, Cardiff, UK.
Pitman
I
I
Penrose-Stevens
A
A
Simpson
B A
BA
Flanagan
P G
PG
D000081:Acetamides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D004359:Drug Therapy, Combination; D016984:Enterococcus faecium / Q000187:drug effects / Q000472:pathogenicity*; D017809:Fatal Outcome; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D006849:Hydrocephalus / Q000628:therapy; D007275:Injections, Intravenous; D007276:Injections, Intraventricular; D007278:Injections, Spinal; D000069349:Linezolid; D008875:Middle Aged; D010080:Oxazoles / Q000627:therapeutic use; D023303:Oxazolidinones; D013345:Subarachnoid Hemorrhage / Q000628:therapy; D014057:Tomography, X-Ray Computed; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use; D017287:Ventriculoperitoneal Shunt / Q000009:adverse effects; D014769:Virginiamycin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000081:Acetamides; D000900:Anti-Bacterial Agents; D010080:Oxazoles; D023303:Oxazolidinones; D014769:Virginiamycin; C113825:quinupristin; D014640:Vancomycin; D000069349:Linezolid; C113826:dalfopristin